News
Sixty seconds on . . . the cost of semaglutide
BMJ 2023; 382 doi: https://doi.org/10.1136/bmj.p2009 (Published 31 August 2023) Cite this as: BMJ 2023;382:p2009
- Zosia Kmietowicz
- The BMJ
The new wonder drug?
Some have called it that. The injectable glucagon like peptide-1 (GLP-1) receptor agonist, also called by its brand name Wegovy, is in high demand among celebrities wanting to lose weight and doctors wanting to prescribe it to patients with obesity or type 2 diabetes, for whom the drug was originally licensed.
Can’t it prevent heart attacks too?
Apparently. Results of the Select trial of over 17 000 people showed that semaglutide reduced the risk of major cardiovascular events …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.